Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Date:1/19/2011

60;There are two main forms of Pompe disease: adult onset with an incidence of one in 57,000 births and infantile onset with an incidence of one in 138,000 births.  Prognosis with standard of care is stabilization of the disease or minor improvements for the majority of adult onset patients.About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in Phase 1/2 development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in Phase 1/2 development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets  has announced the addition of ... to their offering. This newly published ... publication available covering the neurotechnology industry. The report takes ... growth rates in four key segments of the neurotechnology ... the number of systems to be sold, worldwide revenue, ...
(Date:9/22/2014)... , Sept. 22, 2014 Children,s National ... Monday, Sept. 29 at 5 p.m. EDT for ... competition, in response to continued strong interest from ... each will be awarded to the winning presentations ... Innovation Symposium hosted by Children,s National in October. ...
(Date:9/22/2014)... 2014 Decision Resources Group finds that by the ... be worth $2 billion (U.S. dollars), increasing at a compound ... years (to 2018). This growth comes as Chile ... and 4.9 percent expected over the next three to five ... but highly competitive. The pharmaceutical market is dominated by prescription ...
Breaking Medicine Technology:The Market for Neurotechnology: 2014-2018 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
(Date:9/22/2014)... RI (PRWEB) September 22, 2014 Severe weather can ... of time. That’s why, as part of National Preparedness Month, ... and your family prepare for the unexpected:, , ... well as nonperishable food and one gallon of water per person ... Create an evacuation plan that includes pets so your family ...
(Date:9/22/2014)... / Westchester County, NY (PRWEB) September 22, 2014 ... (NYGPS) has joined the Department of Surgery at the ... named Mount Sinai Doctors New York Group for Plastic ... lower Hudson Valley access to a team of world-renowned ... techniques. Additionally, C. Andrew Salzberg, MD, who led ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... The report segments the global physiotherapy equipment ... The equipment segment accounted for a lion’s share ... However, the accessories segment is expected to grow ... owing to the rising demand of physiotherapy services ... are the fastest-growing segments in the physiotherapy equipment ...
(Date:9/22/2014)... critical information systems, such as medical records in ... new approach to computer security that authenticates users ... automatically logs them out when they leave or ... terminal. , Dartmouth,s Trustworthy Health and Wellness ... at the IEEE Symposium on Security & ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... Patient Satisfaction Scores Through Implementing the RROHC Bundle of ... Feb. 27 -- Hansten Healthcare PLLC , a ... and skill development and improving patient satisfaction scores, today ... company as faculty and RROHC Master Coach. , ...
... LAS VEGAS, Feb. 27 Orthopaedic surgeon David ... Specialty Societies (BOS), of the American Academy of Orthopaedic ... Meeting. Dr. Polly will also sit on the Academy,s ... in the Department of Orthopaedic Surgery at the University ...
... United States have used yeast and mammalian cells to ... Parkinson,s disease. , Yeasts are single cell organisms, ... that of cells found in animals and humans. Yeasts ... and offer the ability to screen or test thousands ...
... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... procedure pursuant to Law 223/1991 concerning its Bresso, Italy, ... total of 62 employees. Within 75 days of ... Trade Unions, will review solutions that may reduce the ...
... shares poetry author,s two-year period of severe depressionBROOKLYN, N.Y., ... Arthur F. Temple kept a journal, in which the ... had become intolerable, and the result is this fascinating ... ).In nearly 100 poems, Temple shares his heartfelt feelings ...
... Driven by Demand for Branded Products- Adjusted Diluted EPS ... 2009 Adjusted EPS Guidance Range of $2.59 - $2.67CHADDS ... ENDP ) today reported double-digit percentage growth in ... the fourth quarter and full year ended December 31, ...
Cached Medicine News:Health News:Relationship and Results Oriented Healthcare Announces New Faculty With Impressive Patient Satisfaction Scores 2Health News:David W. Polly Jr., MD, Elected Secretary of Academy Board of Specialty Societies 2Health News:How yeast is helping us to understand Parkinson's Disease 2Health News:How yeast is helping us to understand Parkinson's Disease 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 2Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 4Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 5Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... on patented microplate agglutination technology. Its is ... donor ABO/Rh testing. PK7200 also handles weak ... antibody detection. The Automated Microplate System delivers ... proven reliability that for the past generation ...
... Tecan Haemotyper is an automated ... The Tecan Haemotyper combines a ... platform with the DiaMed agglutination ... process DiaMed-ID cards and microplates ...
... Since the early 1990s, the "Reversed" ... shoulder surgeons with great success. More recently, ... United States have begun to champion this ... go with it. This reversed technology is ...
Medicine Products: